OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
Want to cut your energy bills? Here’s how five experts are doing it 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
NEWTON, Mass., May 31, 2017 -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences:
- The Jefferies 2017 Global Healthcare Conference on Tuesday, June 6, 2017 at 9:00 a.m. ET in New York.
- The JMP Securities Life Science Conference on Tuesday, June 20, 2017 at 2:00 p.m. ET at the St. Regis Hotel in New York.
A live webcast of the Jefferies presentation will be available on the "Events & Presentations" page in the Investors section of the Company's website at http://investors.karyopharm.com/events.cfm. A replay of the Jefferies webcast will be archived on the Company's website for 30 days following the presentation.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. Karyopharm's SINE™ compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). The Company's initial focus is on seeking regulatory approval and commercialization of its lead drug candidate, oral selinexor (KPT-330). To date, over 2,000 patients have been treated with selinexor and it is currently being evaluated in several mid- and later-phase clinical trials across multiple cancer indications, including multiple myeloma in combination with low-dose dexamethasone (STORM) and backbone therapies (STOMP), diffuse large B-cell lymphoma (SADAL), and liposarcoma (SEAL), among others. Karyopharm will soon be initiating a pivotal randomized Phase 3 study of selinexor in combination with bortezomib (Velcade®) and low-dose dexamethasone (BOSTON) in patients with multiple myeloma. In addition to single-agent and combination activity against a variety of human cancers, SINE™ compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm, which was founded by Dr. Sharon Shacham, currently has five investigational programs in clinical or preclinical development. For more information, please visit www.karyopharm.com.
Contacts: Michelle Carroll (212) 600-1902 [email protected] Media: Eliza Schleifstein (917) 763-8106 [email protected]
